Within Europe, Sweden is frontrunner when it comes to public biotech market value. After several years of being in the third position, Belgium now ranks second, achieved in a timeframe of less than 10 years. Remarkably, based on average market value per company, Belgian public biotech companies rank the first with an average of € 300m market cap.
On this page, we make the comparison between mid-2012 and mid-2010.
The graph beneath shows the combined market capitalization of Europe’s public small&midcap biotech companies (market cap cut-off at <€ 1bn), grouped per country.
Remarkably, based on average market value per company, Belgian public biotech companies rank the first with an average of € 300m market cap (bars in gray indicate countries with only one company, hence, the average value is not representative).
In 2010 Belgium took the third position, following Sweden and Great Britain (see graph beneath). Between 2010 and 2012, 5 countries lost at least one company, while the others remained stable in number of listed biotech SMEs (for Belgium this is due to the acquisition of Movetis and its subsequent delisting).